Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 1, 2005 - Issue 4
Submit an article Journal homepage
305
Views
95
CrossRef citations to date
0
Altmetric
Review

Functional interactions between P-glycoprotein and CYP3A in drug metabolism

Uwe Christians University of Colorado Health Sciences Center, Clinical Research & Development, Department of Anesthesiology, 4200 East Ninth Ave., Room UH-2122, Campus Box B-113, Denver, Colorado 80262, USA. [email protected]
,
Volker Schmitz University of Colorado Health Sciences Center, Clinical Research & Development, Department of Anesthesiology, 4200 East Ninth Ave., Room UH-2122, Campus Box B-113, Denver, Colorado 80262, USA. [email protected]
&
Manuel Haschke University of Colorado Health Sciences Center, Clinical Research & Development, Department of Anesthesiology, 4200 East Ninth Ave., Room UH-2122, Campus Box B-113, Denver, Colorado 80262, USA. [email protected]
Pages 641-654 | Published online: 30 Nov 2005

Bibliography

  • WACHER J, WU CY, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and cancer chemotherapy. Mol. Carcinogen (1995) 13:129–134.
  • NELSON DR, KOYMANS L, KAMATAKI T et al. : P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics (1996) 6:1–42.
  • DOMANSKI TL, FINTA C, HALPERT JR, ZAPHIROPOULOS PG: cDNA cloning and initial characterization of CYP3A43, a novel cytochrome P450. Mol. Pharmacol. (2001) 59:386–392.
  • RENDIC S, DI CARLO FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab. Rev. (1997) 29:413–580.
  • AOYAMA T, YAMANO S, WAXMAN DJ et al. : Cytochrome P450 hPCN3, a novel cytochrome P450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for metabolism of steroid hormones and cyclosporine. J. Biol. Chem. (1989) 264:10388–10395.
  • WRIGHTON SA, BRIGHTON WR, SARI MA et al. : Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. (1990) 38:207–213.
  • WESTLIND-JOHNSSON A, MALMEBO S, JOHANSSON A et al. : Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. (2003) 31:755–761.
  • PATKI KC, VON MOLTKE LL, GREENBLATT DJ: In vitro metabolism of midazolam, triazolam, nifedipine and testosterone by human liver microsomes and recombinant cytochromes P450: role of cyp3a4 and cyp3a5. Drug Metab. Dispos. (2003) 31:938–944.
  • SCHUETZ JD, BEACH DL, GUZELIAN PS: Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics (1994) 4:11–20.
  • KOCH I, WEIL R, WOLBOLD R et al. : Interindividual variability and tissuespecificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos. (2002) 30:1108–1114.
  • GOTTESMAN MM, PASTAN I: Biochemistry of multi-drug resistance mediated by the multi-drug transporter. Ann. Rev. Biochem. (1993) 62:385–427
  • CHEN CJ CHIN JE UEDA K et al. : Internal duplication and homology with bacterial transport proteins in mdr1 (P-glycoprotein) gene from multi-drug resistant human cells. Cell (1996) 47:381–389.
  • AMBUDKAR SV, DEY S, HRYCYNA CA, RAMACHANDRA M, PASTAN I, GOTTESMAN MM: Biochemical, cellular, and pharmacological aspects of multidrug transporters. Ann. Rev. Pharmacol. Toxicol. (1999) 39:361–398.
  • SCHINKEL AH, WAGENAAR E, VAN DEEMTER L et al. : Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J. Clin. Invest. (1995) 96:1698–1705.
  • XU C, LI CY, KONG AN: Induction of Phase I, II and III drug metabolism/ transport by xenobiotics. Arch. Pharm. Res (2005) 28:249–268.
  • WU CY, BENET LZ: Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. (2005) 22:11–23.
  • CHRISTIANS U: Transport proteins and intestinal metabolism. P-glycoprotein and cytochrome P4503A. Ther. Drug Monit. (2004) 26:104–106.
  • BENET LZ, CUMMINS CL, WU CY: Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. (2004) 277:3–9.
  • BENET LZ, CUMMINS CL, WU CY: Transport-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. (2003) 4:393–398.
  • BENET LZ, CUMMINS CL: The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev (2001) 50:S3–S11.
  • CUMMINS CL, JACOBSEN W, BENET LZ: Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. (2002) 300:1036–1045.
  • CUMMINS CL, JACOBSEN W, CHRISTIANS U, BENET LZ: CYP3A4 transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J. Pharmacol. Exp. Ther. (2004) 308:143–155.
  • JOHNSON BM, CHARMAN WN, PORTER CJH: Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. Drug Metab. Dispos. (2003) 31:1151–1160.
  • CUMMINS CL, SALPHATI L, REID M, BENET LZ: In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat singlepass intestinal perfusion model. J. Pharmacol. Exp. Ther. (2003) 305:306–314.
  • LAMPEN A CHRISTIANS U GONSCHIOR AK et al. : Metabolism of the macrolide immunosuppressant tacrolimus by the pig mucosa in the Ussing chamber. Br. J. Pharmacol. (1996) 117:1730–1734.
  • LAMPEN A, ZHANG Y, HACKBARTH I, BENET LZ, SEWING KF, CHRISTIANS U: Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J. Pharmacol. Exp. Ther. (1998) 285:1104–1112.
  • SOLDNER A, BENET LZ, MUTSCHLER E, CHRISTIANS U: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br. J. Pharmacol. (2000) 129:1235–1243.
  • ZIMMERMANN C, GUTMANN H, HRUZ P et al. : Mapping of multidrug resistance-associated protein isoforms 1 to 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos. (2005) 33:219–224.
  • MOULY S, PAINE MF: P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res. (2003) 20:1595–1599.
  • FRICKER G, DREWE J, HUWYLER J, GUTMANN H, BEGLINGER C: Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. (1996) 118:1841–1847.
  • KAMINSKY LS, ZHANG QY: The small intestine as a xenobiotic-metabolizing organ. Drug Metab. Dispos. (2003) 31:1520–1525.
  • PAINE MF, KHALIGHI M, FISHER JM et al. : Characterization of intestinal and intraintestinal variations in human CYP3Adependent metabolism. J. Pharmacol. Exp. Ther. (1997) 283:1552–1562.
  • ZHANG QY, DUNBAR D, OSTROWSKA A, ZEISLOFT S, YANG J, KAMINSKY LS: Characterization of human small intestinal cytochromes P450. Drug Metab. Dispos. (1999) 27:804–809.
  • WU CY, BENET LZ: Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin cyclosporine, and GG918. Drug Metab. Dispos. (2003) 31:1292–1295.
  • LAU YY, WU CY, OKOCHI H, BENET LZ: Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme transporter interplay. J. Pharmacol. Exp. Ther. (2004) 308:1040–1045.
  • LAM JL, BENET LZ: Hepatic microsome studies are insufficient to characterize in vivo metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab. Dispos. (2004) 32:1311–1316.
  • MAGLICH JM, SLUDER AE, WILLSON TM, MOORE JT: Beyond the human genome: examples of nuclear receptor analysis in model organisms and potential for drug discovery. Am. J. Pharmacogenomics (2003) 3:345–353.
  • FRANCIS GA, FAYARD E, PICARD F, AUWERX J: Nuclear receptors and the control of metabolism. Ann. Rev. Physiol. (2003) 65:261–311.
  • SYNOLD TW, DUSSAULT I, FORMAN BM: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. (2001) 7:584–590.
  • DUSSAULT I, LIN M, HOLLISTER K, WANG EH, SYNOLD TW, FORMAN BM: Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. (2001) 276:33309–33312.
  • ROSENFELD JM, VARGAS R, XIE W, EVANS RM: Genetic profiling defines xenobiotics gene network controlled by the nuclear receptor pregnane X receptor. Mol. Endocrinol. (2003) 17:1268–1282.
  • BURK O, KOCH I, RAUCY J et al. : The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is metadiated by the xenobiotoc sensors pregnane X receptor (PXR) and the constitutively activated receptor (CAR). J. Biol. Chem. (2004) 279:38379–38385.
  • MAGLICH JM, STOLTZ CM, GOODWIN B, HAWKINS-BROWN D, MOORE JT, KLIEWER SA: Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotics detoxification. Mol. Pharmacol. (2002) 62:638–646.
  • CHERRINGTON NJ, HARTLEY DP, LI N, JOHNSON DR, KLAASSEN CD: Organ distribution of multi-drug resistance proteins 1, 2, and 3 (MRP 1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androsterane receptor activators in rats. J. Pharmacol. Exp. Ther. (2002) 300:97–104.
  • LAMBA JK, LIN YS, SCHUETZ EG, THUMMEL KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. (2002) 54:1271–1279.
  • CHOWBAY B, ZHOU S, LEE EJD: An interethnic comparison of polymorphisms of the genes encoding drug metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab. Rev. (2005) 37:327–378.
  • LIN YS, DOWLING ALS, QUIGLEY SD et al. : Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. (2002) 62:162–172.
  • SAI K, KANIWA N, ITODA M et al. : Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics (2003) 13:741–757.
  • KUEHL P, ZHANG J, LIN Y et al. : Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. (2001) 27:383–391.
  • EICHELBAUM M, FROMM MF, SCHWAB M: Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. (2004) 26:180–185.
  • ANGLICHEAU D, LEGENDRE C, THERVET E: Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation (2004) 78:311–315.
  • MARLOZINI C, PAUS E, BUCLIN T et al. : Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. (2004) 75:13–33.
  • MACPHEE IA, FREDERICKS S, TAI T et al. : Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation (2002) 74:1486–1489.
  • GOTO M, MASUDA S, KIUCHI T et al. : CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics (2004) 14:471–478.
  • HESSELINK DA, VAN SCHAIK RHN, VAN DER HEIDEN IP et al. : Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. (2003) 74:245–254.
  • BONHOMME-FAIVRE L, DEVOCELLE A, SALIBA F et al. : MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver transplant recipients. Transplantation (2004) 78:21–25.
  • ANGLICHEAU D, THERVET E, ETIENNE I et al. : CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. (2004) 75:422–433.
  • ANGLICHEAU D, LE CORRE D, LECHATON S et al. : Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am. J. Transplant. (2005) 5:595–603.
  • FREDERICKS S, HOLT DW: Pharmacogenomics of immunosuppressive drug metabolism. Curr. Opin. Nephrol. Hypertens. (2003) 12:607–613.
  • DIRKS NL, HUTH B, YATES CR et al. : Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int. J. Clin. Pharmacol. Ther. (2004) 42:701–718.
  • AMEYAW MM, REGATEIRO F, LI T et al. : MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 11:217–221.
  • HUSTERT E, ZIBAT A, PRESECAN-SIEDEL E et al. : Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. (2001) 29:1454–1459.
  • ZHANG J, KUEHL P, GREEN ED et al. : The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics (2001) 11:555–572.
  • HAUFROID V, MOURAD M, VAN KERCKHOVE V et al. : The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 14:147–154.
  • LOWN KS, MAYO RR, LEICHTMAN AB et al. : Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. (1997) 62:248–260.
  • EAP CB, BUCLIN T, HUSTERT E et al. : Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur. J. Clin. Pharmacol. (2004) 60:231–236.
  • LEEDER JS, KEARNS GL: Pharmacogenetics in pediatrics: implications for practice. Pediatr. Clin. North Am. (1997) 44:55–77.
  • MACHADO CG, CALADO RT, GARCIA AB et al. : Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T-lymphocytes. Braz. J. Med. Biol. Res. (2003) 36:1653–1657.
  • MIKI Y, SUZUKI T, TAZAWA C, BLUMBERG B, SASANO H: Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multi-drug resistance gene 1 in human adult and fetal tissues. Mol. Cell. Endocrinol. (2005) 231:75–85.
  • CUMMINS CL, WU CY, BENET LZ: Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. (2002) 72:474–489.
  • WOBOLD R, KLEIN K, BURK O et al. : Sex is a major determinant of CYP3A4 expression in human liver. Hepatology (2003) 38:978–988.
  • PAINE MF, LUDINGTON SS, CHEN ML, STEWART PW, HUANG SM, WATKINS PB: Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab. Dispos. (2005) 33:426–433.
  • LAMPEN A, CHRISTIANS U, GUENGERICH FP et al. : Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions and interindividual variability. Drug Metab. Dispos. (1995) 23:1315–1324.
  • CHRISTIANS U, BLECK JS, LAMPEN A et al. : Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after coadministration of diltiazem? Transplant. Proc. (1996) 28:2159–2161.
  • HUANG SM, LESKO LJ: Drug-drug, drug dietary, drug-citrus fruit and other food interactions: what have we learned? J. Clin. Pharmacol. (2004) 44:559–569.
  • FUJITA K: Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metab. Interact. (2004) 20:195–217.
  • HARRIS RZ, JANG GR, TSUNODA S: Dietary effects on drug metabolism and transport. Clin. Pharmacokinet. (2003) 42:1071–1088.
  • LOWN KS, BAILEY DG, FONTANA RJ et al. : Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. (1997) 99:2545–2553.
  • ZHOU S, LIM LY, CHOWBAY B: Herbal modulation of P-glycoprotein. Drug Metab. Rev. (2004) 36:57–104.
  • MORGAN ET: Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev. (1997) 29:1129–1188.
  • IBER H, SEWER MB, BARCLAY TB: Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab. Rev. (1999) 31:29–41.
  • SUKHAI M, PIQUETTE-MILLER M: Regulation of the multidrug resistance genes by stress signals. J. Pharm. Pharmaceut. Sci. (2000) 3:268–280.
  • TENG S, PIQUETTE-MILLER M: The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J. Pharmacol. Exp. Ther. (2005) 312:841–848.
  • CHRISTIANS U SPIEKERMANN K BADER A et al. : Cyclosporine metabolite pattern in blood from patients with acute liver GVHD after bone marrow transplantation. Bone Marrow Transplant (1993) 12:27–33.
  • CHRISTIANS U, SEWING KF: Ciclosporin metabolism in transplant patients. Pharmacol. Ther. (1993) 57:291–345.
  • TROTTER JF, OSBORNE JC, HELLER M, CHRISTIANS U: Effect of hepatitis C on tacrolimus doses and blood levels in liver transplantation recipients. Aliment. Pharmacol. Ther. (2005) 22:37–44.
  • HESSELINK DA VAN HEST RM MATHOT RA et al. : Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. (2005) 5:987–994.
  • BJÖRNSSON TD, CALLAGHAN TJ, EINOLF HJ et al. : The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J. Clin. Pharmacol. (2003) 43:443–469. Websites

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.